Qiagen N.V. is a biotechnology company providing Sample to Insight solutions for molecular testing. The company offers core products comprising kits, instruments, and bioinformatics tools to enable the extraction of meaning from genetic material. Key applications include TB Management, Transplant, Infectious Disease, Oncology, and Sexual & Reproductive Health. Qiagen serves customers globally, including scientists, pharma R&D teams, and clinical labs. Notable platforms and tools include QIA Agent, an AI tool for product comparison and method building, GeneGlobe for exploring targets and pathways, and the Workflow Configurator for designing experimental workflows. The company also provides QIA Agent for automated clinical sample extraction and enzymes for molecular biology. Qiagen operates through subsidiaries in multiple countries and serves a diverse customer base worldwide.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Diagnostics & Research Homepage qiagen.com
Sector Healthcare IR page corporate.qiagen.com/English/investor-relations/overview/default.aspx
Tags
molecular diagnostics, sample preparation, nucleic acid extraction, bioinformatics, clinical testing, oncology, infectious disease, transplant, sexual health, laboratory automation, QIA Agent, GeneGlobe, Workflow Configurator
Press page qiagen.com/th/newsroom

Metrics

Valuation  
Market cap $ 9.492B
Market cap (USD) $ 9.492B
P/E 22.56
PEG 171.82
P/BV 2.51
P/S 4.54
P/OCF 14.51
P/FCF 20.94
Dividend yield 0.57%
Turnover / mcap —
Returns  
ROE 11.6%
ROI 7.8%
ROIC 7.4%
Profit margin 20.3%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 0.13%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 43.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 39
Quality score 36.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Revenue 2.09B 1.978B 1.965B 2.142B 2.252B 1.87B 1.526B 1.502B 1.418B 1.338B 1.281B 1.345B 1.302B 1.254B 1.17B 1.087B
Net profit 424.88M 83.591M 341.303M 423.211M 512.599M 359.188M -41.455M 190.38M 40.394M 80.404M 127.103M 116.634M 69.073M 129.506M 96.038M 144.311M
Free cash flow 453.277M 506.377M 309.745M 586.04M 449.097M 325.019M 212.893M 249.723M 196.698M 267.066M 219.719M 201.374M 174.489M 142.884M 157.974M 171.086M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Share price 44.97 44.53 — — 18.51 51.72 33.86 — 31.46 28.02 27.65 23.46 23.81 18.13 13.83 —
Price performance 12m 0.01 — — — -0.64 0.53 — — 0.12 0.01 0.18 -0.01 0.31 0.31 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 278M 329M 352M 385M 381M 362M 324M 382M 349M 403M
↳ YoY growth +1.6% +18.3% +6.8% +9.5% -1.2% -4.8% -10.6% +18.0% -8.5% +15.3%
↳ 5y CAGR +3.8% +5.6% +6.2% +7.7% +6.8% +5.4% -0.3% +1.7% -1.9% +1.1%
Borrowings, current (USD) — 0.00 503M 285M 42.5M 848M 390M 588M 53.5M 0.00
Borrowings, non-current (USD) 1.07B 1.76B 1.67B 1.42B 1.88B 1.09B 1.47B 922M 1.34B 1.65B
Lease liabilities (USD) — — — 18.7M 23.5M 22M 93.6M 101M 121M 158M
Cash and deposits (USD) 439M 658M 1.16B 624M 598M 881M 731M 668M 664M 839M
Intangible assets (USD) 557M 499M 475M 632M 726M 627M 545M 527M 304M 386M
Right-of-use assets (USD) — — — — — 101M 95.5M 105M 116M 153M
Net debt (borrowings + leases - cash) (USD) 628M 1.1B 1.02B 1.1B 1.35B 1.08B 1.22B 943M 849M 973M
Cash flow detail
Operating cash flow (USD) 342M 287M 359M 331M 458M 639M 715M 459M 674M 654M
Purchases of property, plant and equipment (USD) -74.5M -90.1M -110M -118M -133M -190M -129M -150M -167M -201M
Purchases of intangible assets (USD) -19.4M -34.3M -41M -157M -172M -16.6M -20.1M -13.1M -4.07M -6.08M
Change in receivables (cash effect) (USD) -12.2M -34.2M -41.8M -39.6M -14.7M -7.4M 15.5M -55.1M 12.2M -36.4M
Change in inventories (cash effect) (USD) -20.3M -21.6M -36.9M -30M -108M -81.8M -62M -44.8M 87.8M -848,000
Change in payables (cash effect) (USD) -1.47M 4.32M 6.99M 9.25M 8.44M -5.98M -1.76M -22.4M 1.45M -8.42M
Dividends paid (cash effect) (USD) — — — — — — — 0.00 0.00 -54.2M
Share buybacks (cash effect) (USD) 0.00 -61M -105M -74.5M -64M -100M 0.00 0.00 -292M -280M
Interest paid (cash effect) (USD) -18.2M -20.3M -25.9M -29.7M -25.4M -21.6M -23.2M -20.3M -24.2M -29.3M
Income taxes paid (cash effect) (USD) -22.7M -40.5M -29.3M -41.5M -42.6M -102M -98.6M -82.4M -15.7M -17.3M
Share-based compensation (USD) 28.3M 34.4M 40.1M 65.9M 40.9M 38.4M 49.5M 47.1M 43.6M 50.4M
Operating cash flow before change in receivables (USD) 354M 321M 401M 370M 473M 646M 700M 515M 661M 691M
Free cash flow (OCF - PPE - intangibles) (USD) 248M 162M 209M 56M 154M 432M 566M 297M 502M 447M
Income detail
Research and development expense (USD) 176M 154M 162M 157M 149M 190M 190M 199M 193M 188M
↳ 5y CAGR +6.2% +4.7% +2.1% -0.8% +0.3% +1.5% +4.3% +4.2% +4.2% +4.7%
Total comprehensive income (USD) 6.27M 153M 99.6M -40.4M 425M 430M 346M 312M 42.9M 522M
Comprehensive income to owners (USD) 5.72M 153M 99.6M -40.4M 425M 430M 346M 312M 42.9M 522M
Provision for credit losses (USD) 2.1M 3.1M 4.4M 8.7M 16.4M 18,000 4.48M -2.87M 4.2M 1.14M
Credit cost ratio (credit losses / average receivables) (%) 0.8% 1.0% 1.3% 2.4% 4.3% 0.0% 1.3% 0.8% 1.1% 0.3%
Reported Mar 6, 2017 Mar 6, 2019 Mar 6, 2019 Mar 5, 2021 Mar 5, 2021 Mar 13, 2023 Mar 13, 2023 Mar 20, 2026 Mar 20, 2026 Mar 20, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

QIAGEN reports full Q3 2026 results Bull 0 Bear 1 Results

•Q3 2026 results:

◦Net sales of $548 million rise 3% and also 3% at constant exchange rates (CER)

◦Adjusted operating income margin of 30.4% rises 0.8 percentage points

◦Diluted EPS of $0.51; adjusted diluted EPS of $0.65 ($0.65 CER)

◦Operating cash flow of $447 million for first nine months of 2026

•Due to the pending transaction with EQT Private Equity, QIAGEN has suspended its 2026 outlook and will not provide financial guidance while the transaction is pending

Venlo, the Netherlands, and Germantown, Maryland, November 4, 2026 - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced full results for the third quarter of 2026, with net sales and adjusted diluted earnings per share (EPS) ahead of the outlook.

In line with preliminary results, Q3 2026 sales rose 3% to $548 million compared with Q3 2025, also increasing 3% at constant exchange rates (CER) and exceeding the outlook for about 1-2% CER growth. Consumables and related revenues rose 3% CER and were 91% of sales, while instrument sales rose 1% CER. Sales from the pillars rose 7% CER to $415 million, partly offset by a 7% CER decline in the rest of the portfolio.

business combinatIon agreement Bull 8 Bear 0 Takeover offer

relating to

Project Quail

between

Crown NL Bidco B.V.

and

Dated 21 October 2026

Contents

Clause Page

1.1 Definitions 8

1.2 Construction 8

2 The Offer 10

2.1 Buyer Undertakings; Preparations of the Offer 10

2.2 Offer Consideration 10

2.3 Certainty of Funds 11

2.4 Announcement of the Offer 11

2.5 Submission of Offer Documents 12

2.6 Commencement of the Offer and Filing of the Schedule TO 13

2.7 Submission of the Reasoned Position Statement and the Schedule 14D-9 15

2.8 Acceptance Period and Settlement 16

2.9 No Additional Purchases 18

2.10 SEC Exemptions and Relief 18

2.11 Withholding 19

3 Recommendation and support 19

3.1 Recommendation 19

3.2 Support 20

3.3 Fairness Opinions 22

3.4 Intervening Event 23

3.5 Foundation Call Option 24

4 Financing 24

4.1 Payment of the Settlement Amounts 24

4.2 Equity Financing 25

4.3 Debt Financing 26

4.4 Amendments and Alternative Debt Financing 27

4.5 Interim Bridge Facility Documentation 28

4.6 Reasonable Best Efforts 30

4.7 Cooperation by the Company 30

4.8 No Condition for Completion 34

5 Offer Conditions 35

5.1 Offer Conditions 35

5.2 Waiver 38

5.3 Announcement 39

2 / 89

5.4 Reasonable Best Efforts; Info

QIAGEN reports preliminary Q3 2026 results Bull 0 Bear 0 Results

October 21, 2026

DownloadPDF Format (opens in new window)

Further Information

Weitere Informationen

Press releasePDF PressemitteilungPDF

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary third-quarter 2026 financial results. Net sales were $548 million at both reported and constant exchange rates (CER). Adjusted diluted earnings per share (EPS) were $0.65, also $0.65 CER.

QIAGEN plans to report full Q3 2026 results on Wednesday, November 4, 2026, at approximately 22:05 Frankfurt time / 16:05 New York time.

Given the announced transaction with EQT Private Equity, QIAGEN has suspended its full-year 2026 outlook while the transaction is pending. QIAGEN will also not hold a conference call for its Q3 2026 results.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and Molecular Diagnostics (clinical healthcare). As of September 30, 2026, QIAGEN employed about 5,400 people across more than 35 locations. For more information, visit www.qiagen.com .

**
Important Notice**

Forward-looking Statements

Certain statements contained in this communication may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN N.V.’s (“QIAGEN”) products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. These include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in QIAGEN’s most recent Annual Report on Form 20-F. For further information, please refer to QIAGEN’s filings with the U.S. Securities and Exchange Commission (the “SEC”).

The forward-looking statements in this communication also include statements relating to the tender offer. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include risks and uncertainties relating to: the proposed transaction not being timely completed, if completed at all; uncertainties as to the number of QIAGEN ordinary shares that will be tendered in the tender offer; the possibility that competing offers will be made; the possibility that the conditions to the tender offer may not be satisfied or waived; the occurrence of any event, change or other circumstance that could give rise to the termination of the business combination agreement; the completion of the post-closing measures and implementation of the financing arrangements contemplated in connection with the tender offer; the receipt of, and any conditions associated with, any exemptive or other relief requested from the SEC in connection with the tender offer; regulatory approvals required for the transaction not being timely obtained, if obtained at all, or being obtained subject to conditions; prior to the completion of the transaction, QIAGEN’s business experiencing disruptions due to transaction-related uncertainty or other factors making it more difficult to maintain relationships with employees, customers, licensees, other business partners or governmental entities; difficulty retaining key employees; and the outcome of any legal proceedings related to the proposed transaction. The forward-looking statements contained in this communication speak only as of the date of this communication. Neither the Bidder, EQT Private Equity nor QIAGEN undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable law.

Additional Information and Where to Find it

The tender offer referenced herein has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any ordinary shares of QIAGEN or any other securities, nor is it a substitute for the tender offer materials that the Bidder will file with the SEC and publish in Germany. The terms and conditions of the tender offer will be published in, and the offer to purchase ordinary shares of QIAGEN will be made only pursuant to, the Offer Document and related offer materials prepared by the Bidder and as approved by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, “BaFin”). Once the necessary permission from BaFin has been obtained, the Offer Document and related offer materials will be published in Germany and also filed with the SEC in a tender offer statement on Schedule TO at the time the tender offer is commenced. QIAGEN intends to file a solicitation / recommendation statement on Schedule 14D-9 with the SEC with respect to the tender offer; in addition, QIAGEN will publish a document combining the recommendation statement pursuant to Section 27 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz - “WpÜG”) and the position statement pursuant to Section 18 and Annex G of the Dutch Decree on public offers (Besluit openbare biedingen Wft). The Offer Document for the tender offer (in German and in English) containing the detailed terms and conditions of, and other information relating to, the tender offer will, among other things, be published on the internet at www.eqt-offer.com .

Acceptance of the tender offer by shareholders that are resident outside Germany and outside of the United States may be subject to further legal requirements and/or restrictions. With respect to the acceptance of the tender offer outside Germany and outside of the United States, no responsibility is assumed for the compliance with such legal requirements applicable in the respective jurisdiction.

THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION / RECOMMENDATION STATEMENT ON SCHEDULE 14D-9, AS THEY MAY BE AMENDED FROM TIME TO TIME, AS WELL AS QIAGEN’S RECOMMENDATION STATEMENT PURSUANT TO SECTION 27 WPÜG AND POSITION STATEMENT PURSUANT TO SECTION 18 AND ANNEX G OF THE DUTCH DECREE ON PUBLIC OFFERS (Besluit openbare biedingen Wft) WILL CONTAIN IMPORTANT INFORMATION. INVESTORS AND SHAREHOLDERS OF QIAGEN ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY, AND NOT THIS DOCUMENT, WILL GOVERN THE TERMS AND CONDITIONS OF THE TENDER OFFER, AND BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT SUCH PERSONS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR ORDINARY SHARES.

The tender offer materials, including the offer to purchase and the related letter of transmittal and certain other tender offer documents, and the solicitation/recommendation statement on Schedule 14D-9 (when they become available) and other documents filed with the SEC by the Bidder or QIAGEN, may be obtained free of charge at the SEC’s website at www.sec.gov or at the Bidder’s website at www.eqt-offer.com . In addition, the Bidder’s tender offer statement and other documents it will file with the SEC will be available at www.eqt-offer.com . Furthermore, copies of the Offer Document will also be available free of charge by contacting the information agent to be identified in the Offer Document.

Governing Law

The tender offer will be made and implemented under the laws of the Federal Republic of Germany, in particular the WpÜG, certain applicable provisions of the laws of the Netherlands and certain applicable provisions of the securities laws of the United States of America. Any agreement that is entered into as a result of accepting the tender offer will be exclusively governed by the laws of the Federal Republic of Germany and is to be interpreted in accordance with such laws.

Acquisition of Shares Outside the Tender Offer

Each of EQT Private Equity and the Bidder reserves the right, within the limits of applicable law and subject to any exemptive relief from the SEC, to directly or indirectly acquire shares in QIAGEN outside of the tender offer, whether on or off the stock exchange. Any such purchases or arrangements will be made outside the United States and in compliance with applicable law and subject to any exemptive relief from the SEC. To the extent such acquisitions occur, information about them, including the number of, and the price for, the acquired shares in QIAGEN will be published without undue delay, if and to the extent required under the applicable statutory provisions.

Information in respect of EQT XI

Any information in respect of the EQT XI fund (“EQT XI”) contained herein does not constitute an offer to sell, nor a solicitation of an offer to buy, any security, and may not be used or relied upon in connection with any offer or solicitation of EQT XI. Any offer or solicitation in respect of EQT XI will be made only through a confidential private placement memorandum and related documents which will be furnished to qualified investors on a confidential basis in accordance with applicable laws and regulations. Any securities of EQT XI referred to herein have not been and will not be registered under the Securities Act and may not be offered or sold without registration thereunder or pursuant to an available exemption therefrom. Any offering of securities of EQT XI to be made in the United States would have to be made by means of an offering document that would be obtainable from the issuer or its agents and would contain detailed information about the issuer of the securities and its management, as well as financial information. Any EQT XI securities may not be offered or sold in the United States absent registration or an exemption from registration.

**
QIAGEN contacts**

P****ublic Relations
e-mail: [email protected]

Investor Relations
e-mail: [email protected]

View all news Alle Neuigkeiten ansehen

Twitter Linked In Facebook

IR Contacts

Daniel-Wendorff

Daniel Wendorff

Vice President
Head of Investor Relations

Mobile
+49 152 01811322

[email protected]

Download VCARD

Domenica-Martorana

Dr. Domenica Martorana

Associate Director Global Investor Relations

Mobile
+49 152 018 11244

[email protected]

Download VCARD

Alexandra Koenig

Alexandra Koenig

Investor Relations Coordinator

Mobile
+49 152 018 11709

[email protected]

Download VCARD

Press Contacts

John Gilardi

John Gilardi

Vice President
Head of Corporate Communications
Global

Germany: +49 2103 29 11711

Mobile: +49 152 018 11711

[email protected]

Lisa Specht

Lisa Specht

Manager Public Relations
Corporate Communications

Germany: +49-2103-29-14181

Mobile: [+49-152-018-11381](tel:+49 152 018 11670)

[email protected]

Jana Radoi

Jana Radoi

Corporate Communications Coordinator
Global

Mobile: [+49 152 018 11670](tel:+49 152 018 11670)

[email protected]

Heeyoung Lee

Heeyoung Lee

Asia-Pacific region topics

South Korea: [+82 226265788](tel:+82 226265788) Mobile: [+82 01093389650](tel:+82 01093389650)

[email protected]

Natalia Silo

Natalia Silo

Latin America region topics

Mobile: [+55 11 98702 0137](tel:+82 01093389650)

[email protected]

Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At QIAGEN N.V., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the unsubscribe section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to QIAGEN N.V. to send you the requested Investor Email Alert updates.

* Required

Um sich für E-Mail-Benachrichtigungen für Anleger anzumelden, geben Sie bitte Ihre E-Mail-Adresse in das unten stehende Feld ein und wählen Sie mindestens eine Benachrichtigungsoption aus. Nach dem Absenden Ihrer Anfrage erhalten Sie eine Aktivierungs-E-Mail an die angegebene E-Mail-Adresse. Sie müssen den Aktivierungslink anklicken, um Ihr Abonnement abzuschließen. Sie können sich jederzeit für weitere Benachrichtigungsoptionen anmelden.

QIAGEN N.V. verpflichtet sich, Ihre Daten mit Respekt zu behandeln und sie nicht an Dritte weiterzugeben. Sie können alle von Ihnen abonnierten Investor Alerts abbestellen, indem Sie den unten stehenden Abschnitt "Abbestellen" besuchen. Sollten Sie Probleme mit diesem Vorgang haben, wenden Sie sich bitte an uns, um weitere Unterstützung zu erhalten.

Durch die Angabe Ihrer E-Mail-Adresse erklären Sie sich damit einverstanden, dass QIAGEN N.V. Ihnen die angeforderten Investor Email Alert Updates zusendet.

* Erforderlich

Email Address *

Mailing Lists *
Press Releases Events Presentations SEC-Filings End of Day Stock Quote

Unsubscribe

Abmelden

Email Alert Sign Up Confirmation

Anmeldebestätigung E-Mail-Alarm

Follow Us

Prompts

Qiagen N.V. (ticker QGEN), listed in United States.

ETFs Holding Qiagen N.V.

ETF Weight in ETF Shares Market value As of
EPSB 2.00% 2,989 $ 149.121K Nov 13, 2026
HELX 0.48% 3,419 $ 133.683K Jun 30, 2026
AIVL 0.46% 49,466 $ 1.934M Jun 30, 2026
TOUS 0.41% 156,206 $ 6.428M Jul 31, 2026
DFIS 0.35% 400,923 $ 20.086M Nov 12, 2026
DFIC 0.12% 373,211 $ 18.698M Nov 12, 2026
INRO 0.11% 12,982 $ 646.633K Nov 16, 2026
DFSI 0.09% 21,265 $ 1.065M Nov 12, 2026
DFAX 0.07% 165,675 $ 8.3M Nov 12, 2026
DXIV 0.05% 2,574 $ 128.957K Nov 12, 2026
SFGV 0.04% 9,971 $ 500K Nov 18, 2026
MSSM 0.03% 5,069 $ 219.437K Aug 31, 2026
DFAI 0.02% 69,881 $ 3.501M Nov 12, 2026
VSLU 0.01% 1,567 $ 61.27K Jun 30, 2026
AVDE 0.01% 39,688 $ 1.977M Nov 16, 2026
AVSD 0.01% 482 $ 24.008K Nov 16, 2026
MSLC 0.01% 7,819 $ 338.485K Aug 31, 2026